Growth Hormone Deficiency – Epidemiology – Mature markets
Clarivate Epidemiology’s coverage of growth hormone deficiency (GHD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed incidence for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s GHD forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GHD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following GHD patient populations:
- Diagnosed incident cases of GHD.
- Diagnosed lifetime prevalent cases of GHD.
